8 completed, 1 no longer available. 6 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
| Phase 1 | 3 | Completed 3 |
Follow apilimod: new trials by email Literature Review of apilimod trials Research Report on apilimod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LAM-002A for the Prevention of Progression of COVID-19 Apilimod Dimesylate Capsule, Placebo - COVID-19 Disease | Phase 2 | Completed | IRulya Therapeutics Inc. | 142 | 2020-07-15 | 2023-08-08 |
| A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma LAM-002A, Rituximab, Atezolizumab - Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic | Phase 1 | Completed | IRulya Therapeutics Inc. | 62 | 2015-10-01 | 2024-08-22 |
| STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency STA-5326 - Common Variable Immunodeficiency | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2005-12-02 | 2017-07-02 |
| A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes STA 5326 mesylate, Placebo - Active, Moderate to Severe Rheumatoid Arthritis | Phase 2 | Completed | Synta Pharmaceuticals Corp. | 35 | 2005-12-01 | 2014-02-04 |
| The Immunological and Blood Effects of STA-5326 Mesylate on Patients With Crohn's Disease STA-5326 - Crohn's Disease | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 12 | 2005-11-03 | 2017-07-02 |
| Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease STA-5326 mesylate - Crohn's Disease | Phase 2 | Completed | Synta Pharmaceuticals Corp. | 12 | 2005-11-01 | 2008-12-04 |
| Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease STA-5326 mesylate - Crohn's Disease | Phase 2 | Completed | Synta Pharmaceuticals Corp. | 282 | 2005-08-01 | 2008-12-04 |
| STA-5326 in Crohn's Disease Patients STA-5326 - Crohn's Disease | Phase 1 / Phase 2 | Completed | Synta Pharmaceuticals Corp. | 48 | 2004-02-01 | 2005-06-24 |
| An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD) LAM-002A - Frontotemporal Dementia | No longer available | IRulya Therapeutics Inc. | 2022-08-02 |
Crohn Disease (4) · COVID-19 (1) · Common Variable Immunodeficiency (1) · Coronavirus Infections (1) · Frontotemporal Dementia (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Malabsorption Syndromes (1) · Motor Activity (1)
Synta Pharmaceuticals Corp. (4) · IRulya Therapeutics Inc. (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2)
United States (7) · Canada (1) · Netherlands (1)
Bruce Sands, MD (1) · Langdon Miller, MD (1) · Peter Mannon, MD (1)